益盛药业(002566) - 2014 Q1 - 季度财报

Financial Performance - Revenue for Q1 2014 reached ¥171,807,372.44, an increase of 21.09% compared to ¥141,878,888.44 in the same period last year [6] - Net profit attributable to shareholders was ¥17,198,580.59, reflecting a growth of 9.71% from ¥15,676,619.58 year-on-year [6] - Basic earnings per share improved by 14.29%, reaching ¥0.08 compared to ¥0.07 in the previous year [6] - The weighted average return on equity rose slightly to 1.03% from 0.99% year-on-year [6] - The company expects net profit attributable to shareholders for the first half of 2014 to be between CNY 47,830,100 and CNY 57,396,100, representing a growth of 0% to 20% compared to the same period in 2013 [23] - The increase in net profit is attributed to enhanced marketing efforts, implementation of a comprehensive budget management system, and investment in principal-protected financial products [23] Cash Flow and Investments - The net cash flow from operating activities decreased significantly by 347.56%, resulting in a negative cash flow of ¥116,694,418.06 compared to a positive ¥47,138,760.67 in the previous year [6] - Cash received from operating activities increased by 20.61% compared to the previous period, mainly due to an increase in government subsidies [17] - Cash paid for purchasing goods and accepting services increased by 550.53% compared to the previous period, primarily due to increased procurement of red ginseng and ginseng planting [17] - Cash recovered from investments amounted to CNY 206,730,000, mainly from the redemption of maturing financial products [17] - Cash received from investment income was CNY 1,301,857.68, attributed to returns from financial products [17] - Cash paid for investments totaled CNY 216,600,000, primarily for purchasing financial products [17] - Cash received from borrowings was CNY 60,000,000, due to an increase in short-term borrowings [17] Assets and Liabilities - Total assets increased by 6.57% to ¥2,014,862,823.43 from ¥1,890,655,248.82 at the end of the previous year [6] - The company's inventory rose by 43.90%, primarily due to increased purchases of ginseng and expanded ginseng cultivation [15] - Short-term borrowings increased by 60%, driven by heightened working capital needs [15] Operating Expenses - Sales expenses surged by 30.24%, attributed to increased sales and enhanced market development investments [15] Government Support and Trading - The company received government subsidies amounting to ¥2,211,189.63, contributing to a 130.15% increase in other operating income [15] - The company is currently planning to issue shares for asset acquisition, leading to a temporary suspension of trading since April 1, 2014 [18] - The company will fulfill its information disclosure obligations during the trading suspension, providing updates every five working days [18]